FierceBiotech

Stelara Shows Greater Efficacy than Etanercept for Treatment Of Moderate-To-Severe Plaque Psoriasis

Toronto, ON, (January 14, 2010) -Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA® (ustekinumab) with Enbrel* (etanercept) in the treatment of ...
The Mercury

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn’s Disease

SPRING HOUSE, Pa., May 23, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA (R) (ustekinumab) in Crohn’s disease (CD) ...
Main Line

STELARA(R) (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly ...

SPRING HOUSE, Pa., July 9, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA (R) ...

Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: ...
The Reporter

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn’s Disease

SPRING HOUSE, Pa., May 23, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA (R) (ustekinumab) in Crohn’s disease (CD) ...